BioSpace News Archive

Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date.

Healthcare Integrated Technologies, Inc. (“HITC”) is pleased to announce a batch of initial patent filings, which establishes their initial portfolio with ten provisional applications.

Azitra, Inc., a clinical-stage medical dermatology biotech company addressing serious skin conditions by harnessing the microbiome, announced that Richard Andrews, President and Chief Executive Officer, is scheduled to present an overview of the company at the upcoming Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case.

Researchers from NJIT and CHOP identified sites of methylation that could not be found with existing sequencing methods

Radiologic Associates of Fredericksburg welcomes three new radiologists to the practice: Drs. Paul Mathew, Jacqueline Alvarez, and Alex Skidmore.

Surfaces contaminated with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, pose a threat to the safety of healthcare providers, schools, office workers, and essential businesses, who face the risk of contracting COVID-19 in their workplace

ASH published new guidelines to help older adults with acute myeloid leukemia and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.

ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira’s MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. ImmVira’s MVR-T3011 onco